# A SIMPLIFIED ACUTE PHYSIOLOGY SCORE IN THE PREDICTION OF ACUTE ALUMINUM PHOSPHIDE POISONING OUTCOME

SHAHIN SHADNIA, OMID MEHRPOUR<sup>1</sup>, KAMBIZ SOLTANINEJAD<sup>2</sup>

# ABSTRACT

BACKGROUND: Aluminum phosphide (AIP) is used as a fumigant. It produces phosphine gas, which is a mitochondrial poison. Unfortunately, there is no known antidote for AIP intoxication, and also, there are few data about its prognostic factors. AIMS: The aim of this study was to determine the impact of the Simplified Acute Physiology Score II (SAPS,,) in the prediction of outcome in patients with acute AIP poisoning requiring admission to the Intensive Care Unit (ICU). MATERIALS AND METHODS: This was a prospective study in patients with acute AIP poisoning, admitted to the ICU over a period of 12 months. The demographic data were collected and SAPSII was recorded. The patients were divided into survival and non-survival groups due to outcome. STATISTICAL ANALYSIS: The data were expressed as mean  $\pm$  SD for continuous or discrete variables and as frequency and percentage for categorical variables. The results were compared between the two groups using SPSS software. **RESULTS:** During the study period, 39 subjects were admitted to the ICU with acute AIP poisoning. All 39 patients required endotracheal intubation and mechanical ventilation in addition to gastric decontamination with sodium bicarbonate, permanganate potassium, and activated charcoal, therapy with MgSO, and calcium gluconate and adequate hydration. Among these patients, 26 (66.7%) died. SAPSII was significantly higher in the non-survival group than in the survival group (11.88  $\pm$  4.22 vs. 4.31  $\pm$  2.06, respectively) (P < 0.001). CONCLUSION: SAPSII calculated within the first 24 hours was recognized as a good prognostic indicator among patients with acute AIP poisoning requiring ICU admission.

Key words: Aluminum phosphide poisoning, intensive care unit, mortality, phosphine, prognosis, simplified acute physiology score II

Department of Clinical Toxicology, Loghman Hakim Hospital Poison Center, Faculty of Medicine, and Toxicological Research Center, Shahid Beheshti University of Medical Sciences, Tehran, <sup>1</sup>Department of Forensic Medicine, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, <sup>2</sup>Department of Forensic Toxicology, Legal Medicine Research Center, Legal Medicine Organization of Iran, Tehran, Iran

#### Correspondence:

Dr. Kambiz Soltaninejad, Department of Forensic Toxicology, Legal Medicine Research Center, Legal Medicine Organization of Iran, Behesht Street, Khayam Avenue, Tehran-11144, Iran. E-mail: kamsoltaninejad@yahoo.com



# INTRODUCTION

Phosphides are used throughout the world as pesticides to protect stored grains from rodents and other pests.<sup>[1,2]</sup> Solid phosphides, including aluminum phosphide (AIP), form toxic phosphine gas following contact with water, moisture in the air, or hydrochloric acid in the stomach.<sup>[1-4]</sup>

During the past 35 years, high mortality rates have been reported following significant exposures to aluminum, zinc and calcium phosphides. AIP is known as "rice tablet" in Iran and marketed in 3 g tablets under brand name "Phostoxin". Incidence of AIP poisoning in Iran is also comparatively high.<sup>[5-7]</sup> Exposure is rarely accidental with the majority of cases involving intentional suicide acts.[8-12] In Loghman Hakim Hospital Poison Centre (LHHPC) from 1997 to 1998 and in 2003, we encountered 349 and 318 fatalities among 35,580 and 24,179 poisoned patients, respectively, over 12 years of age. Of these fatalities, 2.6 and 2.83%, respectively, cases were due to acute AIP poisoning.<sup>[9,13]</sup> As the incidence and also the mortality rate of AIP poisoning is high in Iran, it should raise the attention of the physician to the problem of acute AIP poisoning and it also necessitates the awareness of the public to the hazards of this poison.[14]

To the best of our knowledge, there are scant data on evaluating markers such as Glasgow Coma Scale (GCS), electrocardiogram (ECG), blood glucose level and scoring systems like Acute Physiology and Chronic Health Evaluation (APACHE) to predict mortality in acute AIP poisoning. Also, in some instances, the role of a single clinical and/or paraclinical finding is inconsistent.<sup>[15,16]</sup> So, we aimed to access the role of Simplified Acute Physiology Score II (SAPS<sub>II</sub>) in estimating the outcome in these kinds of patients.

#### MATERIALS AND METHODS

This was a prospective study on acute AIPintoxicated patients who were treated in the intensive care unit (ICU) of LHHPC as a teaching hospital, over a 12-month period from 1 April 2007 to 1 April 2008.

Acute AIP-intoxicated patients with no history of diabetes, cardiovascular, respiratory, renal and hepatic failure, and no advanced medical management for AIP poisoning in any medical center before admission were included in the study. Establishment of the diagnosis in all cases was based on the history of exposure and clinical manifestations, and other circumstantial evidence such as availability of a poison bottle or a label found by the relatives who brought the case to hospital.

All the patients received gastric decontamination with sodium bicarbonate (44 mEq, orally), permanganate potassium (1:10,000), and activated charcoal (1 g/ kg, orally) in the first 6 hours after onset of poisoning in the Emergency Department (ED). All the patients required endotracheal intubation and mechanical ventilation and were admitted to ICU. They were treated with the same protocol (magnesium sulfate 4–6 g by IV infusion daily, calcium gluconate 4 g by IV infusion daily and adequate hydration) under the supervision of the same physicians and nurses. According to the situation of the patients, some of them were treated with

standard doses of vasopressor drugs like norepinephrine, and dopamine.

The qualifying case records were extracted from the ICU admission office. We collected and abstracted patients' information regarding gender, age, amount of AIP consumed, time between exposure and onset of treatment, signs and symptoms of intoxication on admission time, therapeutic intervention and laboratory tests including arterial blood gas (ABG), ECG, and outcome from the medical records onto a data sheet developed specifically for this study. Data were kept confidential in all stages of the study.

A detailed multiple variable database was created. All data were collected either as dichotomous variables (e.g., gender, outcome) or as numeric variables including continuous (e.g., potassium, sodium, etc.) or discrete (e.g., heart rate, GCS, etc.). GCS, as described by Teasdale and Jennet,<sup>[17]</sup> was calculated at admission on ED. The SAPS<sub>II</sub> was calculated in accordance with the original methodology,<sup>[18]</sup> using the worst physiologic values on the first ICU day. The score chart is shown in Table 1. All the patients were followed up until discharge from the hospital or death. According to the outcome, the patients were divided into survival and non-survival groups.

All data were analyzed with SPSS software version 12. The data were expressed as mean ± SD for continuous or discrete variables and as frequency and percentage for categorical variables. Chi-square test was used for statistical comparison of qualitative variables. The normal distribution of quantitative variables was tested by Kolmogorov–Smirnov test. The statistical comparison was done with Mann– Whitney *U*-test for nonparametric variables and independent student *t* test for parametric variables. *P* values of 0.05 or less were considered to be statistically significant.

The protocol of the study was approved by ethical committee of Shahid Beheshti University of Medical Sciences.

# RESULTS

During the study period, according to inclusion criteria, 39 patients with acute AIP poisoning (21 men, 18 women), of age ranging from 14 to 62 years and with a mean age of 27.56 ± 11.95 years, were studied. In most of the patients (46.15%) the ingested amount was one tablet of AIP; average ingested amount was  $1.38 \pm 0.89$  tablets with a range of 0.25-4 tablets. Average time elapsed between poisoning and admission at the hospital was 3.35 ± 3.5 hours (range 0.3-18 hours). Most of the patients (59%) had vomiting; and systolic blood pressure (SBP) less than 100 mmHg was observed in 37 (94.87%) cases at the time of admission (mean 80.64 ± 17.81 mmHg with the range of 50-130 mmHg). Also, ECG abnormality was found in 17 (43.59%) cases at the time of admission. The evaluation of ABG showed that the pH ranged between 6.7 and 7.55, with a mean value of 7.23  $\pm$  0.19. Also, the results showed that most of the patients (43.59%) had pH between 7.15 and 7.35 at the time of admission. The mean of SAPS, was 9.36 ± 5.11 (range 1–19) [Tables 2 and 3].

Thirteen patients survived and 26 patients died. The mortality rate was about 66.7% (26/39). The route of exposure was deliberate ingestion

#### SAPSII AND ACUTE ALUMINUM PHOSPHIDE POISONING

| Table 1 | Simplified | acute | nhysiology  | score chart |
|---------|------------|-------|-------------|-------------|
|         | Simplineu  | acute | pilysiology |             |

#### Table 1: (contd)

| Table 1: Simplified acute      | physiology s | core chart | Table 1: (contd)                      |                    |
|--------------------------------|--------------|------------|---------------------------------------|--------------------|
| Parameter                      | Findings     | Points     | Parameter                             | Findings           |
| Age (years)                    | ≤45          | 0          | Hematocrit (%)                        | ≥60                |
|                                | 46–55        | 1          |                                       | 50–59.9            |
|                                | 56–65        | 2          |                                       | 46–49.9            |
|                                | 66–75        | 3          |                                       | 30–45.9            |
|                                | >75          | 4          |                                       | 20–29.9            |
| SBP (mmHg)                     | ≥190         | 4          |                                       | <20                |
|                                | 150–189      | 2          | White blood cells count (1000/µL)     | ≥40                |
|                                | 80–149       | 0          |                                       | 20-39.9            |
|                                | 55–79        | 2          |                                       | 15–19.9            |
|                                | <55          | 4          |                                       | 3–14.9             |
| Heart rate (beat/min)          | ≥180         | 4          |                                       | 1–2.9              |
|                                | 140–179      | 3          | Serum glucose (mg/dL)                 | < 1                |
|                                | 110-139      | 2          | Serum glucose (mg/uL)                 | ≥800<br>500–799    |
|                                | 70–109       | 0          |                                       | 250-499            |
|                                | 55-69        | 2          |                                       | 70–249             |
|                                | 40–54        | 3          |                                       | 50-69              |
|                                | 40–34<br><40 | 4          |                                       | 29–49              |
| Glasgow coma scale             | 13–15        | 4<br>0     |                                       | <29                |
| Clasgow coma scale             | 10–12        | 1          | Serum potassium (mEq/L)               | ≥7                 |
|                                | 7–9          | 2          |                                       | 6–6.9              |
|                                | 7-9<br>4-6   | 3          |                                       | 5.5-5.9            |
|                                | 4–0<br>3     | 4          |                                       | 3.5-5.4            |
| Pagniratory rate (breathe/min) |              |            |                                       | 3–3.4              |
| Respiratory rate (breaths/min) | ≥50          | 4          |                                       | 2.5–2.9            |
|                                | 35-49        | 3          |                                       | <2.5               |
|                                | 25-34        | 1          | Serum sodium (mEq/L)                  | ≥180               |
|                                | 12-24        | 0          |                                       | 161–179            |
|                                | 10–11        | 1          |                                       | 156–160            |
|                                | 6–9          | 2          |                                       | 151–155            |
|                                | 3–5          | 3          |                                       | 130–150            |
|                                | <3           | 4          |                                       | 120–129            |
| Body temperature (°C)          | ≥41          | 4          |                                       | 110–119            |
|                                | 39-40.9      | 3          |                                       | <110               |
|                                | 38.5–38.9    | 1          | Blood urea nitrogen (mg/dL)           | ≥154               |
|                                | 36-38.4      | 0          |                                       | 101–153            |
|                                | 34–35.9      | 1          |                                       | 81-100             |
|                                | 32-33.9      | 2          |                                       | 21-80              |
|                                | 30–31.9      | 3          |                                       | 10-20              |
|                                | <30          | 4          | Serum HCO <sub>3</sub> (mEq/L)        | <10<br>≥40         |
| Urinary output (L/24 hours)    | ≥5           | 2          |                                       | ≥40<br>30–39.9     |
|                                | 3.5-4.99     | 1          |                                       | 20–29.9<br>20–29.9 |
|                                | 0.7–3.49     | 0          |                                       | 20–29.9<br>10–19.9 |
|                                | 0.5–0.69     | 2          |                                       | 5-9.9              |
|                                | 0.2–0.49     | 3          |                                       | <5                 |
|                                | <0.2         | 4          | Scores are obtained in the first 24 h |                    |

Table (contd...)

hours of admission; Scores are score = summation of the points for each item

Points

|                             |   | Num | nber     | Per   | cent          |  |
|-----------------------------|---|-----|----------|-------|---------------|--|
| Age (years)                 |   |     |          |       |               |  |
| 12–19                       |   | 12  |          | 30.77 |               |  |
| 20–39                       |   | 20  |          | 51.28 |               |  |
| 40–59                       |   | 6   |          | 15.38 |               |  |
| ≥60                         |   | 1   |          | 2.    | 57            |  |
| Sex                         |   |     |          |       |               |  |
| Male                        |   | 21  |          | 53.85 |               |  |
| Female                      |   | 18  | В        | 46    | .15           |  |
| Number of AIP tablets       |   |     |          |       |               |  |
| <1                          |   | 8   |          | 20.51 |               |  |
| 1                           | 1   |     | 18       |       | 46.15         |  |
| 2                           |   | 8   |          | 20.51 |               |  |
| 3                           |   | 4   |          | 10.26 |               |  |
| 4                           |   | 1   |          | 2.57  |               |  |
| Clinical signs and symptoms |   |     |          |       |               |  |
| Hypotension                 | SBP $\leq$ 70 mmHg<br>70 < SBP $\leq$ 90 mmHg | 37  | 14<br>23 | 94.87 | 3784<br>62.16 |  |
| Vomiting                    | _   | 23  | 3        | 58    | .97           |  |
| Tachycardia                 |   | 10  | 6        | 41    | .03           |  |
| Abdominal pain              |   | 12  | 2        | 30    | .77           |  |
| Thirst                      |   | 1   | 1        | 28    | .21           |  |
| Bradycardia                 |   | 8   | 3        | 20    | .51           |  |
| Agitation                   |   | 1   |          | 2.    | 57            |  |
| Paraclinical findings       |   |     |          |       |               |  |
| рН                          | pH < 7.15                                     | 13  |          | 33.33 |               |  |
|                             | 7.15 ≤ pH < 7.35                              | 17  |          | 43.59 |               |  |
|                             | 7.35 ≤ pH < 7.45                              | 5   |          | 12.82 |               |  |
|                             | 7.45 ≤ pH                                     | 4   | ł        | 10    | .26           |  |
|                             | ST-T change                                   |     | 8        |       | 47.6          |  |
| ECG abnormality             | Ischemic change                               | 17  | 3        | 43.59 | 17.65         |  |
|                             | Dysrhythmia                                   |     | 6        |       | 35.29         |  |

| Table 2: Distribution of patients due to age, sex, number of ingested AIP tablets, clinical and paraclinical |
|--|
| manifestations   |

in all patients. There was no significant difference between survival and non-survival groups in age, gender, ingested amount of AIP tablets, time interval between the onset of poisoning and admission at hospital, respiratory rate, serum sodium, potassium,  $HCO_3$ , and  $PaCO_2$  at the time of admission to the hospital [Table 3].

As illustrated in Table 3, a significant difference was observed between survival and non-survival

groups with respect to immediate vomiting after the onset of poisoning, GCS, SBP, pulse rate, serum pH, ECG abnormality, hematocrit, white blood cell count, blood glucose, serum blood urea nitrogen and  $SAPS_{\parallel}$  at the time of admission in the hospital.

#### DISCUSSION

AIP poisoning is a major health problem with a high mortality rate in Iran and other countries,

| Parameter (normal range)   | All patients (n=39)                 | Survival group<br>(n = 13) | Non-survival group<br>(n = 26) | Р     |  |
|--|-------------------------------------|----------------------------|--------------------------------|-------|--|
|  | Mean ± SD (range)                   |                            |                                |       |  |
| Sex  |                                     |                            |                                |       |  |
| Male   | 21                                  | 7                          | 14                             | 1     |  |
| Female   | 18                                  | 6                          | 12                             |       |  |
| Age (years)  | 27.56 ± 11.95 (14 - 62)             | 24.62 ± 7.56               | 29.65 ± 14.48                  | 0.31  |  |
| Systolic blood pressure<br>(<140 mmHg)                               | 80.64 ± 17.81 (50 - 130)            | 90.77 ± 11.88              | 75.58 ± 18.29*                 | 0.01  |  |
| Pulse rate<br>(60 – 100 beats/min)                                   | 99.85 ± 29.78 (35 - 160)            | 115.69 ± 24.98             | 91.92 ± 29.20*                 | 0.02  |  |
| GCS  | 12.08 ± 0.62 (3 - 15)               | $13.92 \pm 0.80$           | 11.15 ± 0.79                   | 0.01  |  |
| Respiratory rate (12 – 20<br>breaths/min)                            | 22.05 ± 9.77 (0 - 55)               | 19.62 ± 6.49               | 23.27 ± 10.96                  | 0.27  |  |
| Hematocrit (35 – 45%)  | 40.64 ± 5.95<br>(29.90 - 58.30)     | 36.38 ± 4.74               | 42.77 ± 5.37**                 | 0.001 |  |
| White blood cells count<br>(7000 – 10,000/µL)                        | 11,800 ± 3437.95<br>(4800 - 18,300) | 10,046.15 ± 2923.93        | 12,676.92 ± 3385.65*           | 0.02  |  |
| Blood glucose level<br>(70 – 110 mg/dL)                              | 198.69 ± 93.46 (68 - 432)           | 150.23 ± 55.58             | 222.92 ± 99.81*                | 0.04  |  |
| Serum potassium<br>(3.5 – 5.5 mEq/L)                                 | 3.92 ± 0.63 (2.60 - 6)              | $3.86 \pm 0.43$            | 3.95 ± 0.72                    | 0.67  |  |
| Serum sodium<br>(135 – 155 mEq/L)                                    | 140.15 ± 5.14 (130 – 152)           | 136.69 ± 4.09              | $140.38 \pm 5.65$              | 0.70  |  |
| Blood urea nitrogen<br>(7 – 18 mg/dL)                                | 20.51 ± 11.04 (11 - 60)             | 26.92 ± 10.64              | 17.31 ± 9.94*                  | 0.002 |  |
| Serum HCO <sub>3</sub> (22 – 26 mEq/L)                               | 11.61 ± 4.38 (3.59 – 19)            | $12.30 \pm 3.90$           | $11.26 \pm 4.64$               | 0.49  |  |
| SAPSII   | 9.36 ± 5.11 (1 – 19)                | 4.31 ± 2.06                | 11.88 ± 4.22**                 | 0.001 |  |
| PaCO <sub>2</sub> (35 – 45 mmHg)                                     | 28.15 ± 12.44 (16 – 65)             | 24.57 ± 8.23               | 29.93 ± 13.88                  | 0.32  |  |
| pH on admission time<br>(7.35 – 7.45)<br>ECG                         | 7.23 ± 0.19 (6.70 – 7.55)           | 7.31 ± 0.12                | 7.19 ± 0.20*                   | 0.04  |  |
| Normal   | 32                                  | 11                         | 11*                            | 0.01  |  |
| Abnormal   | 17                                  | 2                          | 15                             |       |  |
| Time interval between onset<br>of poisoning and admission<br>(hours) | 3.35 ± 3.51 (0.30 – 18)             | 4.26 ± 4.87                | 2.90 ± 2.58                    | 0.53  |  |
| Number of ALP tablets  | 1.38 ± 0.89 (0.25 – 4)              | $1.04 \pm 0.76$            | 1.55 ± 0.91                    | 0.05  |  |
| The use of AIP tablets with water                                    |                                     |                            |                                |       |  |
| Positive   | 4                                   | 4                          | 0*                             | 0.003 |  |
| Negative   | 35                                  | 9                          | 26                             |       |  |
| Immediately vomiting<br>after ingestion                              |                                     |                            |                                |       |  |
| Positive   | 23                                  | 11                         | 12*                            | 0.02  |  |
| Negative   | 16                                  | 2                          | 14                             |       |  |

# Table 3: Comparison of demographic, clinical, paraclinical parameters and $SAPS_{\mu}$ in survival and non-survival groups

Data are mean ± SD. The difference between survival and non-survival groups is significant at \*P < 0.05 and \*\*P < 0.001

especially in developing countries.<sup>[7,15,19]</sup> In this regard, one of the exigent issues in acute AIP poisoning is predicting its outcome. Unfortunately, to date, there have been inadequate studies on the clinical and paraclinical findings to determine the severity and outcome of acute AIP poisoning.<sup>[15,16]</sup>

In this study, we aimed to evaluate  $SAPS_{\parallel}$  which consists of clinical and paraclinical parameters that can be obtained rapidly in cases with AIP poisoning, and could help in determining the outcome of AIP poisoning.

In this study, the prognostic factors were SAPS<sub>II</sub>, low GCS, hypotension, hyperglycemia, acidosis, hemoconcentration, leukocytosis, hyperuremia and ECG abnormalities. Our data were consistent with the results achieved in the previous studies.<sup>[15,16,19,20]</sup>

In some instances, there are inconsistent studies regarding the role of a single clinical and/or paraclinical finding to predict the outcome of acute AIP poisoning.<sup>[16,19,21,22]</sup> Scoring systems like SAPS<sub>II</sub>, which is among the most used of scoring systems in ill patients, and evaluation of the general condition of patients during the first 24 hours<sup>[18]</sup> can be used to predict the outcome of the patients with acute AIP poisoning.

Hajouji Idrissi *et al*, (2006) evaluated the efficacy of APACHE<sub>II</sub> and SAPS<sub>II</sub> to determine the severity of AIP poisoning and found that they were positively correlated with poor outcome.<sup>[20]</sup> In another study, the predictive power of APACHE<sub>II</sub> was evaluated in AIP poisoning.<sup>[16]</sup> Both the APACHE<sub>II</sub> and the SAPS<sub>II</sub> scoring systems demonstrated an ability to predict the mortality rates in this type

of poisoning. As  $SAPS_{II}$  scoring system is a simplified version of the APACHEII scoring system, we evaluated this scoring system in our study, and the results showed a significant difference in  $SAPS_{II}$  between the survival and non-survival groups.

### Limitation

The limitation of our study was the small sample size with regard to the long duration of the study. So, further multicenter studies with larger samples need to be done in the future to conclusively support our results.

# CONCLUSION

According to our findings and previous studies, it can be concluded that  $SAPS_{\parallel}$  scoring system is a reliable index to predict the outcome of the acute AIP poisoning.

# ACKNOWLEDGMENTS

This study was supported by a grant from Toxicological Research Center of Shahid Beheshti University of Medical Sciences. The authors wish to convey their full appreciation to the nurses of Loghman Hakim Hospital Poison Center, especially Mrs. S. Bana-Jafari, Mrs. M. Rezvani, and Mrs. B. Barari for their help.

# REFERENCES

- Cienki JJ. Non-anticoagulant rodenticides. In: Ford MD, Delaney KA, Ling LJ, Erickson T, editors. Clinical toxicology. Philadelphia, PA: WB Saunders; 2001. p. 858.
- Sasser SM. Rodenticides. In: Viccellio P, Bania T, Brent J, Hoffman RS, Kulig KW, Mofenson HC, *et al*, editors. Emergency toxicology. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1998. p. 433.
- 3. Garry VF, Good PF, Manivel JC, Perl DP.

Investigation of fatality from non-occupational aluminum phosphide exposure: Measurement of aluminum in tissue and body fluids as a marker of exposure. J Lab Clin Med 1993;122:739-47.

- Gupta S, Ahlawat SK. Aluminum phosphide poisoning - a review. J Toxicol Clin Toxicol 1995;33:19-24.
- Pajoumand A, Jalali N, Abdollahi M, Shadnia S. Survival following severe aluminum phosphide poisoning. J Pharm Res 2002;32:297-9.
- Shadnia S, Rahimi M, Pajoumand A. Rasouli MH, Abdollahi M. Successful treatment of acute aluminum phosphide poisoning: Possible benefit of coconut oil. Hum Exp Toxicol 2005;24:215-8.
- Abdollahi M, Jalali N, Sabzevari O, Hoseini R, Ghanea T. A retrospective study of poisoning in Tehran. J Toxicol Clin Toxicol 1997;35:387-93.
- Moghadamnia AA, Abdollahi M. An epidemiological study of poisoning in northern Islamic Republic of Iran. East Mediterr Health J 2002;8:1-7.
- Shadnia S, Esmaily H, Sasanian G, Pajoumand A, Hassanian-Moghaddam H, Abdollahi M. Pattern of acute poisoning in Tehran-Iran in 2003. Hum Exp Toxicol 2007;26:753-6.
- Nocera A, Levitin HW, Hilton JM. Dangerous bodies: A case of fatal aluminum phosphide poisoning. Med J Aust 2000;173:133-5.
- Popp W, Mentfewitz J, Gotz R, Voshaar T. Phosphine gas poisoning in a German office. Lancet 2002;359:1574.
- Shadnia S, Mehrpour O, Abdollahi M. Unintentional poisoning by phosphine released from aluminum phosphide. Hum Exp Toxicol 2008;27:87-9.
- Jalali N, Pajoumand A, Abdollahi M, Shadnia S. Epidemiological survey of poisoning mortality in Tehran during 1997-1998. Toxicol Lett 2000;116:84.
- 14. Abder-Rahman HA, Battah AH, Ibraheem YM,

Shomaf MS, el-Batainch N. Aluminum phosphide fatalities, new local experience. Med Sci Law 2000;40:164-8.

- Mehrpour O, Alfred S, Shadnia S, Keyler DE, Soltaninejad K, Chalaki N, *et al.* Hyperglycemia in acute aluminum phosphide poisoning as a potential prognostic factor. Hum Exp Toxicol 2008;27:591-5.
- Louriz M, Dendane T, Abidi K, Madani N, Abouqal R, Zeggwagh AA. Prognostic factors of acute aluminium phosphide poisoning. Indian J Med Sci 2009;63:227-34.
- 17. Teasdale G, Jennett B. Assessment of coma and impaired consciousness: A practical scale. Lancet 1974;2:81-4.
- Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-29.
- Shadnia S, Sasanian G, Allami P, Hosseini A, Ranjbar A, Amini-Shirazi N, *et al.* A retrospective 7-years study of aluminum phosphide poisoning in Tehran: Opportunities for prevention. Hum Exp Toxicol 2009;28:209-13.
- Hajouji Idrissi M, Oualili L, Abidi K, Abouqal R, Kerkeb O, Zeggwagh AA, Severity factors of aluminium phosphide poisoning (Phostoxin). Ann Fr Anesth Reanim 2006;25:382-5 [Abstarct].
- Chugh SN, Kishore K, Aggarwal N, Attri S. Hypoglycaemia in acute aluminium phosphide poisoning. J Assoc Physicians India 2000;48: 855-6.
- 22. Mathai A, Singh Bhanu M. Acute aluminium phosphide poisoning: Can we predict mortality? Indian J Anaesth 2010;54:302-7.

Source of Support: Toxicological Research Center of Shahid Beheshti University of Medical Sciences. Conflict of Interest: None declared. Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.